Nama's AI scorecard currently rates United Therapeutics Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is UTHR's P/E ratio?

United Therapeutics trades at a trailing price-to-earnings ratio of 21.2.

When does UTHR report earnings?

United Therapeutics's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $7.43.

What is the UTHR price target?

The median analyst price target from 14 analysts is $698.50, with a range of $368.00 – $850.00.

Is UTHR Shariah compliant?

Nama's AAOIFI-style screen reads United Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

United Therapeutics (UTHR)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

United Therapeutics (UTHR) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $23.94B, a trailing price-to-earnings ratio of 21.2 and a free-cash-flow yield of 3.9%. Over the most recent reported fiscal year, revenue grew 10.6% and free cash flow per share fell 3.0%. Nama's AI scorecard rates it Buy, 6.3 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 6.3/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +20.0% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-8.5%

How far the last close sits under the highest price of the past five years.

Market cap	$23.94B
Trailing P/E	21.2
Price / book	3.8
Price / sales	7.6
FCF yield	3.9%
Dividend yield	—
Gross margin	86.1%
Operating margin	44.5%
Net margin	41.6%
Revenue growth (YoY)	+10.6%
Revenue growth (3-yr annual)	+18.0%
EPS growth (YoY)	+10.4%
FCF/share growth (YoY)	-3.0%
Beta	0.5
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

UTHR earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $7.43). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$5.71	$6.04	-5.5%	$832.50M
Q2 2026	Aug 5, 2026	$7.27	$6.86	+6.0%	$783.30M
Q1 2026	May 6, 2026	$5.82	$6.86	-15.2%	$781.50M
Q4 2025	Feb 25, 2026	$7.70	$6.76	+13.9%	$790.20M

UTHR analyst price target

Median target $698.50 from 14 analysts, ranging $368.00 – $850.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3
RDY	Dr. Reddy's Laboratories	$12.43B	20.4

Explore live UTHR data on Nama Insights →

Recent Congressional trades

United Therapeutics trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Lisa McClain	House	Sell	$1,001 - $15,000	Nov 21, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Nov 21, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025

UTHR FAQ

Is UTHR a buy?: Nama's AI scorecard currently rates United Therapeutics Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is UTHR's P/E ratio?: United Therapeutics trades at a trailing price-to-earnings ratio of 21.2.
When does UTHR report earnings?: United Therapeutics's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $7.43.
What is the UTHR price target?: The median analyst price target from 14 analysts is $698.50, with a range of $368.00 – $850.00.
Is UTHR Shariah compliant?: Nama's AAOIFI-style screen reads United Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.